64615

Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)

CPT code 64615 represents a complex and highly specialized therapeutic procedure involving the bilateral chemodenervation of specific muscle groups innervated by the facial, trigeminal, cervical spinal, and accessory nerves. This intervention involves the precise, targeted injection of a neurotoxin, predominantly onabotulinumtoxinA, into designated muscles of the head and neck. It is most frequently indicated for the prophylactic treatment of adult patients suffering from chronic migraine, defined as experiencing headaches on 15 or more days per month, with at least eight of these headache days fulfilling the criteria for migraine, lasting four or more hours, and typically persisting for more than three consecutive months despite the utilization of standard oral preventive medications. The mechanism of action involves the chemodenervating agent binding to presynaptic nerve terminals at the neuromuscular junction, subsequently internalizing and inhibiting the release of acetylcholine and other nociceptive neurotransmitters, such as substance P and calcitonin gene-related peptide (CGRP). This action profoundly alters pain processing pathways and reduces muscle tension that contributes to headache generation. The standard clinical protocol dictates the administration of these injections across multiple predefined anatomical sites, encompassing seven specific muscle areas: the frontalis, procerus, corrugator, temporalis, occipitalis, cervical paraspinal, and trapezius muscles. Utilizing a standardized technique, such as the PREEMPT (Phase III REsearch Evaluating Migraine Prophylaxis Therapy) protocol, the provider maps out approximately 31 standardized injection points, administering specific unit doses at each site to achieve comprehensive peripheral denervation. Additional injections may be tailored to follow the patient specific pain distribution. The entire procedure demands profound anatomical knowledge to avoid unintended paralysis of adjacent muscle groups, minimize adverse events such as ptosis or neck weakness, and maximize therapeutic efficacy. Because the code description explicitly defines the procedure as bilateral, modifier 50 is not appropriate. Practitioners must additionally report the specific medication supply using the appropriate HCPCS Level II code, ensuring exact unit accounting.

Clinical Indications

  • Chronic migraine, defined as headaches on 15 or more days per month for more than 3 months, with at least 8 days being migraines.
  • Failure, intolerance, or contraindication to at least two different classes of oral migraine prophylactic medications.
  • Patient must be an adult (typically 18 years or older) depending on payer policy.
  • Prophylactic management of severe chronic daily headaches meeting specific payer criteria for botulinum toxin therapy.

Procedure Steps

  1. The patient is positioned comfortably, typically seated upright, and the treatment areas of the head and neck are exposed.
  2. The provider identifies and palpates the targeted injection sites across the frontalis, corrugator, procerus, temporalis, occipitalis, cervical paraspinal, and trapezius muscles.
  3. The skin over the targeted injection sites is cleansed using an aseptic technique, commonly with an alcohol swab.
  4. The botulinum toxin is reconstituted with sterile, preservative-free 0.9 percent sodium chloride according to the manufacturer guidelines.
  5. Using a fine-gauge needle, the physician systematically administers precise intramuscular injections into the predefined anatomical sites bilaterally.
  6. Gentle pressure is applied to the injection sites as needed to achieve hemostasis and prevent ecchymosis.
  7. The patient is monitored briefly post-procedure for any immediate adverse reactions.
  8. Post-procedure instructions are provided, advising the patient to remain upright and avoid massaging the injected areas for several hours.

Coding Guidelines

  • Code 64615 inherently includes bilateral injections; do not use modifier 50 (Bilateral procedure).
  • Do not report 64615 in conjunction with 64616 (neck muscle chemodenervation) or 64617 (larynx chemodenervation) when performed on the same muscles.
  • Use the appropriate HCPCS Level II code (e.g., J0585 for onabotulinumtoxinA) to report the supply of the medication used.
  • Document the exact number of units injected and any units discarded using modifier JW for discarded drug or JZ for zero discarded drug, as required.
  • If injections are performed for cosmetic purposes, they are non-covered and should not be billed under 64615.
  • Ensure documentation specifically details the muscles injected, the dosage per muscle, and the medical necessity.
  • If an Evaluation and Management service is billed on the same day, append modifier 25 to the E/M code only if it is significant, separately identifiable, and above the usual pre-operative and post-operative care associated with the injection.

Associated ICD-10 Codes